Evidence required by heath technology assessment and reimbursement bodies evaluating diagnostic or prognostic algorithms that include omics data

International Journal of Technology Assessment in Health Care

23 August 2018 - Multi-analyte assays with algorithmic analyses use combinations of circulating and clinical markers including omics-based sources for diagnostic and/or prognostic purposes. 

Assessing multi-analyte assays (MAAAs) is challenging under existing health technology assessment methods or practices. We undertook a scoping review to explore the HTA methods used for MAAAs to identify the criteria used for clinical research and reimbursement purposes.

This review included only non-companion (stand-alone) tests that are actionable and that have been evaluated by leading HTA or insurer/reimbursement bodies up to September 2017.

Read International Journal of Technology Assessment in Health Care article

Michael Wonder

Posted by:

Michael Wonder